Nanograb
Nanograb designs peptide-LNP targeting systems with biophysics-informed AI so genetic medicines reach a chosen cell type instead of the liver.
Nanograb is a narrow, high-value bet. If your program is stuck on which peptide, which epitope, and which ligand density to carry into synthesis, its physics-informed ranking algorithms and multivalent superselectivity design address the exact decision general lab suites such as Benchling or Syntace skip entirely. It is the right conversation for early-stage gene therapy teams without an in-house peptide design group. It is the wrong buy if you need a validated in vivo delivery protocol today, or if you want to evaluate a platform end-to-end from public documentation — the reachable site is four named capabilities and an email address.
Verified 4d ago · liveness 50/100 · cite: rightaichoice.com/tools/nanograb
- Drug delivery scientists choosing an LNP or peptide targeting strategy before synthesis
- Gene therapy teams selecting a cell-type targeting strategy for a genetic medicine payload
- Nanomedicine labs exploring computationally designed targeting systems
- Early-stage programs without an in-house peptide design group
- Labs that need a validated in vivo delivery protocol available today
- Teams seeking a general lab informatics or ELN suite
- Programs that have already locked their peptide and ligand density and only need synthesis
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip Nanograb if your program needs an experimentally validated in vivo delivery protocol in hand today, or if you have already fixed your peptide and ligand density and only need material synthesized.
Prediction quality depends on how much training data exists for your target cell type, so less-studied targets may need extra design iterations before a candidate is worth synthesizing.
No pricing, plan, or engagement-model information for Nanograb was reachable in this run, so the cost side has to be scoped directly with the company alongside a specific target cell type. For budget context, it competes for the same program dollars as in-house peptide design capacity and as outsourced peptide-LNP design work, not against low-cost lab software seats.
In short
Nanograb — Nanograb designs peptide-LNP targeting systems with biophysics-informed AI so genetic medicines reach a chosen cell type instead of the liver. Best for Drug delivery scientists choosing an LNP or peptide targeting strategy before synthesis, Gene therapy teams selecting a cell-type targeting strategy for a genetic medicine payload, Nanomedicine labs exploring computationally designed targeting systems. Contact Sales pricing.
Viability Score
How well maintained and how widely used is Nanograb? Built from what the vendor actually publishes (docs, changelog, tutorials, integrations, pricing), whether the site is live, and how much real users discuss it. How we calculate this
Last calculated: October 2026
How we score →Key Features
- Biophysics-informed AI models for genetic medicine targeting
- Design of targeting peptides attached to lipid nanoparticles (LNPs)
- Multimodal peptide optimization across candidate sequences
- Physics-informed ranking algorithms to score candidate designs
- Bespoke epitope selection for a chosen cell target
- Multivalent superselectivity design for cell-selective binding
- Ligand density tuning on LNP surfaces to cross binding thresholds
- Particle surface chemistry selection as a design variable
- Targeting any cell in the body rather than default liver uptake
- Computational candidate ranking before committing synthesis budget
- Design-stage targeting output intended to feed into synthesis
About Nanograb
Nanograb develops biophysics-informed AI models for designing targeting systems for genetic medicines. The core deliverable is a design, not a lab workflow: unique combinations of targeting peptides attached to lipid nanoparticles (LNPs) intended to reach any cell in the body. The company's published pillars are multimodal peptide optimization, physics-informed ranking algorithms, bespoke epitope selection, and multivalent superselectivity — the point-of-departure idea being that past a certain ligand density a particle binds one cell type far more strongly than another, turning a generic LNP into a cell-selective one. In practice you bring a target cell type and get candidate peptide, epitope, and surface-chemistry designs ranked computationally before anything is synthesized. It fits drug delivery scientists, gene therapy teams, and nanomedicine labs choosing a targeting strategy without an in-house peptide design group. It is not a lab informatics or ELN suite, and it does not hand you a validated in vivo protocol. Public material is deliberately thin — the reachable site is a short manifesto-style presence listing those four pillars plus a contact address, so any capability beyond them has to be established in a technical conversation.
Behind the Verdict
Nanograb sits in an unusual lane. Most AI-in-biotech products land either as lab operations software (ELN, LIMS, sample tracking) or as general-purpose model APIs. Nanograb does neither. It sells a targeting design: peptides grafted onto lipid nanoparticles, with the peptide sequence, the epitope choice, the ligand density on the particle surface, and the surface chemistry all treated as design variables that get ranked computationally before synthesis budget is committed. The strongest idea in the published material is multivalent superselectivity. Rather than optimizing a single ligand's affinity, the design question becomes how many copies of it to put on the particle — because past a threshold density the binding contrast between target and off-target cells widens sharply. That is a real biophysical lever, and it is the kind of decision a wet-lab-only loop tends to reach slowly and expensively. Pairing it with physics-informed ranking algorithms and multimodal peptide optimization means the output is a ranked candidate list, not a single guess. Where it fits: early-stage genetic medicine programs that know their target cell type but have no in-house peptide design capability, and drug delivery scientists who need to choose an epitope and a surface chemistry before committing synthesis. Where it does not: teams that need an experimentally validated in vivo delivery protocol available now, teams shopping for a general lab informatics suite, and programs that have already locked their peptide and ligand density and only need someone to make the material. Nanograb does not track your experiments — the deliverable is a design. The honest caveat is visibility. The reachable site is a short manifesto listing four pillars and a contact address; there is no product documentation, integration list, or technical detail reachable in this pass, so model accuracy, supported targets, and deployment shape are all open questions. Prediction quality in any learned design platform also depends on how much training data exists for the cell type you care about, which matters most for less-studied targets. Treat the capability list as directional and judge the company in a technical conversation with your specific target in hand.
Researching Nanograb? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Real-world workflow fit
Concrete scenarios for the personas Nanograb actually fits — and what changes day-one when you adopt it.
You know the cell type you need to reach but have no peptide design group in house, so you bring the target to Nanograb and receive ranked peptide-LNP targeting designs covering peptide sequence, epitope choice, ligand density, and surface chemistry before any synthesis purchase order is raised.
Outcome: A ranked candidate set to carry into synthesis instead of an open-ended bench optimization loop, which is the decision general lab informatics suites do not address.
You want to move a payload off default liver uptake and widen the binding contrast between your target and off-target cells, so you use multivalent superselectivity design to tune how many targeting ligands sit on the LNP surface and where that density crosses the binding threshold.
Outcome: A ligand-density and surface-chemistry design you can defend with biophysics reasoning rather than trial and error.
You compare several candidate epitopes for the same target tissue and need to know which combinations are worth the synthesis spend, so Nanograb's physics-informed ranking algorithms order the candidates computationally first.
Outcome: Synthesis budget concentrated on the highest-ranked targeting designs, with the lower-ranked options documented rather than made.
Use Cases
- Design peptide-LNP targeting systems for a chosen cell type in a gene therapy program
- Rank candidate peptide sequences for an LNP before committing synthesis budget
- Select epitopes for bespoke targeting of a specific tissue or cell population
- Apply multivalent superselectivity to widen binding contrast between target and off-target cells
- Deliver genetic medicines aimed at cells other than the liver in systemic dosing
Models Under the Hood
as of 2026-09-09
Limitations
- Public material on Nanograb is genuinely thin.
- The reachable site is a short manifesto-style page listing multimodal peptide optimization, physics-informed ranking algorithms, bespoke epitope selection, and multivalent superselectivity, plus a contact address — no product documentation, changelog, or integration list was available in this run.
- Anything beyond those four named capabilities, including model accuracy, supported target cell types, and deployment options, has to be established in a technical conversation rather than from published material.
- Prediction quality for any computational design platform also depends on available training data for the cell type you care about, a caveat that matters most for less-studied targets.
as of 2026-10-13
Verification history
We have re-verified Nanograb 9 times since . Each pass re-reads the vendor's own pages and re-checks every listed field against that evidence; passes where nothing had changed are marked as such.
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-checked, vendor evidence unchanged
- — re-checked, vendor evidence unchanged
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
Showing the 6 most recent of 9 verification passes.
Free to cite with attribution — this page re-verifies continuously.
Where the pricing makes sense
The company stage and team size where Nanograb's pricing actually pencils out — and where peers do it cheaper.
No pricing, plan, or engagement-model information for Nanograb was reachable in this run, so the cost side has to be scoped directly with the company alongside a specific target cell type. For budget context, it competes for the same program dollars as in-house peptide design capacity and as outsourced peptide-LNP design work, not against low-cost lab software seats.
Setup time & first value
How long it actually takes to get something useful out of Nanograb — broken out by persona, not the marketing-page minute.
No onboarding, documentation, or implementation material was reached in this run, so no setup estimate can be given. Realistically, the first step is a technical conversation with Nanograb in which you bring a specific target cell type and a synthesis timeline; how long you wait for ranked designs after that is not publicly documented.
Resources & Guides
Tutorials & Learning
YouTube returned 5 videos for “Nanograb”, and we withheld 5: 5 could not be judged, because “Nanograb” is a single word that other videos use for other things. We are showing none, because we could not prove any of them are about Nanograb.
Official links
Tools that pair well with Nanograb
Common stack mates teams adopt alongside Nanograb, with the specific reason each pairing earns its keep.
Insitro
Causal AI drug discovery pairing 20+ petabytes of cellular data with human genetics to find true disease targets
Haplotype Labs
Haplotype Labs builds SaaS and community tooling for population genetics, aiming to cut sequencing costs 50–90% and speed polygenic risk modeling.
Nimbus Therapeutics
Nimbus Therapeutics designs highly selective small-molecule drugs for oncology, immunology, and metabolic disease.
Featured Head-to-Head Comparisons
Nanograb vs Isomorphic Labs
Choose Nanograb if you need a hands-on AI tool for optimizing gene delivery in your lab with affordable freemium access. Choose Isomorphic Labs only if you are a pharma company ready for a multi-year, high-investment partnership to discover new drugs at scale — it is not a plug-and-play product.
Nanograb vs Rapidsos
RapidSOS and Nanograb serve completely different domains – emergency response vs. genetic research. Choose RapidSOS if you run a 911 center or enterprise safety program needing AI-enhanced dispatch and device data; it's deeply embedded in US public safety infrastructure with recent ESInet integration. Choose Nanograb if you're a gene therapy lab looking to reduce trial-and-error in transfection via ML-driven protocol recommendations. No overlap in use cases.
Nanograb vs Codametrix
CodaMetrix and Nanograb serve completely separate domains: CodaMetrix is an enterprise medical coding automation platform for large health systems, while Nanograb is an AI-powered gene delivery optimizer for research labs. A buyer should choose based on their industry—healthcare revenue cycle vs. biotech R&D—as there is no overlap in use cases. CodaMetrix offers proven ROI and KLAS validation; Nanograb provides a freemium entry to accelerate gene therapy experiments.
Alternatives to Nanograb
View allInsitro
Causal AI drug discovery pairing 20+ petabytes of cellular data with human genetics to find true disease targets
Haplotype Labs
Haplotype Labs builds SaaS and community tooling for population genetics, aiming to cut sequencing costs 50–90% and speed polygenic risk modeling.
Nimbus Therapeutics
Nimbus Therapeutics designs highly selective small-molecule drugs for oncology, immunology, and metabolic disease.
Frequently Asked Questions
Categories
Used Nanograb? Help shape our editorial sentiment research.